Available for Partnership


Available for Partnership

AB101 is a long-acting, weekly basal insulin with the potential to transform insulin management by reducing therapeutic burdens and improving compliance. Using a proprietary microsphere platform and uniform pegylated-insulin microspheres, AB101 achieves controlled and sustained long-acting release. It’s unique mechanism of action allows for potential weekly subcutaneous injection.

Preclinical studies demonstrates proof-of-concept in three species and supporting weekly dosing. Doses that were efficacious in animals are translatable to dosing in humans. A first-in-human Phase 1 clinical trial assessing the safety and tolerability, pharmacokinetics and pharmacodynamics of AB101 was completed in the fourth quarter of 2019.

AB101 was generally safe and well tolerated, without dose-limiting side effects or occurrence of sudden insulin release. At the mid- and high-dosing cohorts, administration of AB101 resulted in a slow onset of and sustained increase in insulin levels, and dose-dependent action for greater than seven days. At higher doses, the necessary drug volume was greater than anticipated, as was variability in the absorption profile between patients.

Thus, Rezolute believes that additional formulation development is required before advancing the program further in the clinic and welcomes a motivated partner to continue this mission.

If interested in learning more about the program, please contact